A Retrospective Analysis of Outcomes in Patients with Hepatorenal Syndrome At Methodist Dallas Medical Center

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Hepatorenal syndrome (HRS) is a common cause of acute kidney injury (AKI) in patients with liver disease \[1\]. Increased activity and presence of vasodilators such as nitric oxide in cirrhotic patients leads to vasodilation, especially in the splanchnic circulation, resulting in hemodynamic changes that precipitate renal injury \[1\]. Patients may present with elevated serum creatinine (Cr), benign urine sediment, and low urine sodium \[1\].

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 85
Healthy Volunteers: f
View:

• All patients \>18 years old that were hospitalized between April 1st 2019 and April 1st 2023 who either presented with HRS-AKI or developed a diagnosis of HRS during the hospital course. HRS-AKI will be defined based on the ICA criteria, described below:

‣ Presence of cirrhosis, acute liver failure, or acute-on-chronic liver failure

⁃ An increase in serum Cr of ≥0.3 mg/dL within 48 hours or ≥50% from baseline value and/or urinary output ≤0.5 mL/kg of body weight for ≥6 hours (requires use of a urinary catheter)

⁃ No full or partial response for ≥2 days of diuretic withdrawal and volume expansion with albumin (dosed at 1 g/kg of body weight/day)

⁃ Absence of shock

⁃ No current or recent treatment with nephrotoxic drugs

⁃ Absence of parenchymal renal disease

⁃ Suggestion of renal vasoconstriction based on FENa \<0.2%

Locations
United States
Texas
Liver Institute of Methodist Dallas Medical Center
RECRUITING
Dallas
Contact Information
Primary
Colette Ngo Ndjom, MS
MHSIRB@mhd.com
214-947-1281
Backup
Loretta W Bedell, MPH
mhsirb@mhd.com
214-947-4680
Time Frame
Start Date: 2023-05-13
Estimated Completion Date: 2025-05-13
Participants
Target number of participants: 500
Related Therapeutic Areas
Sponsors
Leads: Methodist Health System

This content was sourced from clinicaltrials.gov